Switch theme
Sign up to access all valuation multiples
Binex Co Ltd is engaged in manufacturing and distribution of pharmaceutical products. The key products include gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as an ointment, creams, and others. It also manufactures biomedicines and raw materials. Its other business operation involved contract development and manufacturing business for other companies. The company invests in some bio ventures that develop biomedicines.
1985
n/a
LTM Revenue $114M
LTM EBITDA -$7.5M
$435M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Binex has a last 12-month revenue (LTM) of $114M and a last 12-month EBITDA of -$7.5M.
In the most recent fiscal year, Binex achieved revenue of $94.5M and an EBITDA of -$17.6M.
Binex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Binex valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $114M | XXX | $94.5M | XXX | XXX | XXX |
| Gross Profit | $30.9M | XXX | $15.5M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 16% | XXX | XXX | XXX |
| EBITDA | -$7.5M | XXX | -$17.6M | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | -19% | XXX | XXX | XXX |
| EBIT | -$9.4M | XXX | -$22.4M | XXX | XXX | XXX |
| EBIT Margin | -8% | XXX | -24% | XXX | XXX | XXX |
| Net Profit | -$11.9M | XXX | -$25.5M | XXX | XXX | XXX |
| Net Margin | -10% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $24.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Binex's stock price is KRW 17530 (or $13).
Binex has current market cap of KRW 542B (or $394M), and EV of KRW 598B (or $435M).
See Binex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $435M | $394M | XXX | XXX | XXX | XXX | $-0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Binex has market cap of $394M and EV of $435M.
Binex's trades at 4.6x EV/Revenue multiple, and -24.7x EV/EBITDA.
Equity research analysts estimate Binex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Binex has a P/E ratio of -33.2x.
See valuation multiples for Binex and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $394M | XXX | $394M | XXX | XXX | XXX |
| EV (current) | $435M | XXX | $435M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | -58.0x | XXX | -24.7x | XXX | XXX | XXX |
| EV/EBIT | -46.5x | XXX | -19.4x | XXX | XXX | XXX |
| EV/Gross Profit | 14.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -33.2x | XXX | -15.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -28.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBinex's last 12 month revenue growth is 36%
Binex's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Binex's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Binex's rule of X is 85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Binex and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Growth | -344% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 47% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Binex acquired XXX companies to date.
Last acquisition by Binex was XXXXXXXX, XXXXX XXXXX XXXXXX . Binex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Binex founded? | Binex was founded in 1985. |
| Where is Binex headquartered? | Binex is headquartered in South Korea. |
| Who is the CEO of Binex? | Binex's CEO is Mr. Hyuk-jong Lee. |
| Is Binex publicy listed? | Yes, Binex is a public company listed on KRX. |
| What is the stock symbol of Binex? | Binex trades under 053030 ticker. |
| When did Binex go public? | Binex went public in 2001. |
| Who are competitors of Binex? | Similar companies to Binex include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Binex? | Binex's current market cap is $394M |
| What is the current revenue of Binex? | Binex's last 12 months revenue is $114M. |
| What is the current revenue growth of Binex? | Binex revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of Binex? | Current revenue multiple of Binex is 3.8x. |
| Is Binex profitable? | Yes, Binex is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Binex? | Binex's last 12 months EBITDA is -$7.5M. |
| What is Binex's EBITDA margin? | Binex's last 12 months EBITDA margin is -7%. |
| What is the current EV/EBITDA multiple of Binex? | Current EBITDA multiple of Binex is -58.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
